News Esperion and Daiichi Sankyo square up on Nexletol milestone Companies can't see eye to eye on the recently reported data from the CLEAR outcomes study.
News Nexletol shows CLEAR benefit in cardiovascular outcome trial Will a 13% improvement in MACE over placebo be enough to lift lacklustre sales growth?
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
